SenzaGen buys UK animal-free drug tester Alcyomics for $2.82M
What's the deal? SenzaGenDealroom has a profile for this one. Try Dealroom → has agreed to acquire AlcyomicsDealroom has a profile for this one. Try Dealroom →, a Newcastle-based specialist in non-animal immunotoxicology testing for drug development. The initial price is roughly US$3.38M, with up to US$3.02M in contingent payments. SenzaGen expects to close the deal around November 4, 2026.
What's the endgame? SenzaGen already sells non-animal testing services, and Alcyomics extends it into preclinical safety testing of biological drugs — key tools in cancer treatment. Alcyomics' Skimune platform combines human skin tissue and immune cells to flag immune-related adverse effects, evaluating therapies such as monoclonal antibodies, T-cell engagers, and bispecifics.
The numbers: Alcyomics generated revenue of about US$2.36M (roughly £1.49 million) in its 2025/2026 financial year, up 46% year on year, with a 24% EBITDA margin. It counts multinational pharmaceutical companies in Europe, the US, and Japan among its customers.
How it's financed: SenzaGen is funding the deal through existing cash and a directed issue of US$3.02M in convertible bonds to its principal owner, Eiffel Investment GroupDealroom has a profile for this one. Try Dealroom →.
Why now? "The shift toward non-animal methods is accelerating," said Peter Nählstedt, SenzaGen's chief executive officer. The US Food and Drug Administration has stepped up efforts to make validated non-animal methods more usable in drug development, including draft guidance on new approach methodologies and clarifications that such methods can support safety assessments.
What could go wrong? A favourable regulatory backdrop does not guarantee demand. Methods must still be scientifically validated and fit the regulatory question, so the key test is whether SenzaGen can convert the broader shift into recurring customer uptake.
The signal: The deal adds a profitable specialist to SenzaGen's business and signals growing commercial appetite for human-based testing, particularly for biologic drugs, as regulators warm to alternatives to animal models.
Read more: hk.marketscreener.com
Image credit: Generated with Gemini
